P
Paul Nathan
Researcher at Northwood University
Publications - 213
Citations - 17048
Paul Nathan is an academic researcher from Northwood University. The author has contributed to research in topics: Melanoma & Trametinib. The author has an hindex of 44, co-authored 181 publications receiving 13804 citations. Previous affiliations of Paul Nathan include John Radcliffe Hospital & Aix-Marseille University.
Papers
More filters
Journal ArticleDOI
Improved Overall Survival in Melanoma with Combined Dabrafenib and Trametinib
Caroline Robert,Boguslawa Karaszewska,Jacob Schachter,Piotr Rutkowski,Andrzej Mackiewicz,Daniil Stroiakovski,Michael Lichinitser,Reinhard Dummer,Florent Grange,Laurent Mortier,Vanna Chiarion-Sileni,Kamil Drucis,Ivana Krajsová,Axel Hauschild,Paul Lorigan,Pascal Wolter,Georgina V. Long,Keith T. Flaherty,Paul Nathan,Antoni Ribas,Antoni Ribas,Anne-Marie Martin,Peng Sun,Wendy A. Crist,Jeff Legos,Stephen D. Rubin,Shonda M Little,Dirk Schadendorf +27 more
TL;DR: Dabrafenib plus trametinib, as compared with vemurafenib monotherapy, significantly improved overall survival in previously untreated patients with metastatic melanoma with BRAF V600E or V600K mutations, without increased overall toxicity.
Journal ArticleDOI
Pazopanib versus Sunitinib in Metastatic Renal-Cell Carcinoma
Robert J. Motzer,Thomas E. Hutson,David Cella,James Reeves,Robert E. Hawkins,Jun Guo,Paul Nathan,Michael Staehler,Paul de Souza,Jaime R. Merchan,Ekaterini Boleti,Kate Fife,Jie Jin,Robert Jones,Hirotsugu Uemura,Ugo De Giorgi,Ulrika Harmenberg,Jinwan Wang,Cora N. Sternberg,Keith C. Deen,Lauren McCann,Michelle D. Hackshaw,Rocco Crescenzo,Lini Pandite,Toni K. Choueiri +24 more
TL;DR: Pazopanib and sunitinib have similar efficacy, but the safety and quality-of-life profiles favor pazoSmithKline Pharmaceuticals.
Journal ArticleDOI
Combined BRAF and MEK Inhibition versus BRAF Inhibition Alone in Melanoma
Georgina V. Long,Daniil Stroyakovskiy,Helen Gogas,Evgeny Levchenko,F. de Braud,James Larkin,Claus Garbe,T. Jouary,Axel Hauschild,Jean-Jacques Grob,V. Chiarion Sileni,Céleste Lebbé,Mario Mandalà,Michael Millward,Ana Arance,Igor Bondarenko,John B. A. G. Haanen,Johan Hansson,Jochen Utikal,Virginia Ferraresi,Nadezhda Kovalenko,Peter Mohr,V. Probachai,Dirk Schadendorf,Paul Nathan,Caroline Robert,Antoni Ribas,Douglas J. DeMarini,Jhangir G. Irani,Michelle Casey,Daniele Ouellet,Anne-Marie Martin,Ngocdiep T. Le,Kiran Patel,Keith T. Flaherty +34 more
TL;DR: A combination of dabraenib and trametinib, as compared with dabrafenib alone, improved the rate of progression-free survival in previously untreated patients who had metastatic melanoma with BRAF V600E or V600K mutations.
Journal ArticleDOI
Improved survival with MEK Inhibition in BRAF-mutated melanoma for the METRIC Study Group
Keith T. Flaherty,Caroline Robert,Peter Hersey,Paul Nathan,Paul Nathan,Claus Garbe,Mohammed M. Milhem,Lev V. Demidov,Jessica C. Hassel,Piotr Rutkowski,Peter Mohr,Reinhard Dummer,Uwe Trefzer,James Larkin,Jochen Utikal,Jochen Utikal,B. Dréno,Michelle Casey,Laurie Sherman,Frank S. Wu,Dirk Schadendorf +20 more
TL;DR: Tametinib, as compared with chemotherapy, improved rates of progression-free and overall survival among patients who had metastatic melanoma with a BRAF V600E or V600K mutation.
Journal ArticleDOI
Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial
Georgina V. Long,Georgina V. Long,Daniil Stroyakovskiy,Helen Gogas,Evgeny Levchenko,Filippo de Braud,James Larkin,Claus Garbe,Thomas Jouary,Axel Hauschild,Jean-Jacques Grob,Vanna Chiarion-Sileni,Céleste Lebbé,Mario Mandalà,Michael Millward,Ana Arance,Igor Bondarenko,John B. A. G. Haanen,Johan Hansson,Jochen Utikal,Jochen Utikal,Virginia Ferraresi,Nadezhda Kovalenko,Peter Mohr,Volodymr Probachai,Dirk Schadendorf,Paul Nathan,Caroline Robert,Caroline Robert,Antoni Ribas,Douglas J Demarini,Jhangir G. Irani,Suzanne Swann,Jeffrey J. Legos,Fan Jin,Bijoyesh Mookerjee,Keith T. Flaherty +36 more
TL;DR: The improvement in overall survival establishes the combination of dabrafenib and trametinib as the standard targeted treatment for BRAF Val600 mutation-positive melanoma.